Can SS-31 and PE-22-28 Work Together to Enhance Mood, Memory, and Heart Health?

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

TREK1 Inhibition and Cardiac Remodeling

Research shows that deletion of TREK-1, a mechanosensitive potassium channel, leads to increased cardiac hypertrophy under pressure overload but surprisingly preserves both systolic and diastolic function. TREK-1 knockout (KO) mice displayed a 39% increase in stroke work and maintained cardiac output following transverse aortic constriction (TAC). Despite genetic signatures typically linked to heart dysfunction—including fetal gene activation, decreased calcium-handling genes, and elevated calcineurin activity—cardiac function remained protected in these mice for up to one year.

These findings suggest that the molecular pathways driving cardiac hypertrophy can be separated from those that control cardiac function, and fibroblasts may play a critical role in determining the heart’s adaptive responses.

Calcineurin/NFAT Activation in Cardiac Hypertrophy

Calcineurin is a calcium-dependent phosphatase that activates nuclear factor of activated T-cells (NFAT). Once activated, NFAT translocates to the nucleus and promotes hypertrophy-related gene expression. In cardiomyocytes, increased calcineurin activity precedes maladaptive cardiac remodeling and contributes to both hypertrophy and cell death through mitochondrial destabilization.

Evidence shows that lowering miR-133a results in elevated calcineurin/NFAT activity, while restoring miR-133a suppresses this pathway and reduces hypertrophy. A reciprocal regulatory loop exists—calcineurin activation lowers miR-133, while miR-133 represses calcineurin—highlighting a delicate balance that determines cardiac outcomes.

SIRT1 and miR-133a: A Feedback System

SIRT1, a longevity-related protein, and miR-133a regulate each other in cardiomyocytes. While miR-133a inhibits SIRT1 expression, SIRT1 itself influences heart development and stress adaptation. Hypoxia strongly upregulates miR-133a in fetal hearts, reducing SIRT1 activity. These dynamics highlight how SIRT1 and miR-133a form a feedback system with consequences for heart development, fibrosis, and hypertrophy.

SS-31 Counters Calcineurin/NFAT-Induced Hypertrophy

Aging is associated with increased activation of calcineurin/NFAT signaling in the heart, driving hypertrophy and reducing mitochondrial stability. SS-31, a mitochondria-targeted peptide, helps counteract this process by improving mitochondrial membrane potential, reducing oxidative stress, and restoring energy production.

Studies demonstrate that SS-31:

• Preserves mitochondrial function in diabetic islet cells.

• Enhances mitochondrial membrane potential.

• Reduces endoplasmic reticulum stress.

• Increases antioxidant pathways via SIRT1/SIRT3.

In a pressure-overload model, continuous SS-31 treatment reduced cardiac hypertrophy by 50% and prevented systolic failure. Additional studies showed SS-31 alleviated sepsis-induced heart injury, improved mitochondrial dynamics in fibroblasts from cardiomyopathy patients, and reduced pulmonary hypertension.

Neuroinflammation as a Link Between Depression and Cardiovascular Disease

Chronic stress and neuroinflammation contribute to both depression and cardiovascular dysfunction. Elevated cytokines such as IL-1β disrupt neurotransmitters like serotonin and BDNF, impairing synaptic plasticity and leading to depressive behaviors. Long-term inflammation also reduces neurogenesis in the hippocampus, shrinks brain volume, and increases dementia risk.

These inflammatory processes connect depression with heart disease, forming a cycle of neurodegeneration and cardiovascular dysfunction.

SS-31 Reduces Neuroinflammation and Oxidative Stress

SS-31 reduces neuroinflammation by activating SIRT1, which deacetylates and suppresses HMGB1—a key regulator of inflammatory signaling. In animal models, this prevented HMGB1 release, reduced systemic inflammation, and improved survival in sepsis and endotoxemia.

Further studies show SS-31:

• Ameliorates oxidative stress in type 2 diabetes.

• Inhibits inflammatory signaling in microglia.

• Improves mitochondrial quality in conditions such as Friedreich’s ataxia.

• Prevents cognitive decline caused by sleep deprivation.

By reducing oxidative stress and restoring mitochondrial function, SS-31 supports both neuroprotection and cardiovascular resilience.

SS-31 and PE-22-28 Improve Memory and Neuroplasticity

SS-31 restores synaptic plasticity proteins impaired by sleep deprivation, including NMDA receptors, p-CREB, and BDNF. It also improves mitochondrial function, enhances synaptic structure, and reverses learning and memory deficits in inflammation-related cognitive impairment models.

PE-22-28, another peptide, enhances serotonin release, has a 24-hour half-life, boosts CREB activity, and doubles markers of neurogenesis in the hippocampus. These actions improve spatial learning, short-term memory, and mood regulation.

Together, SS-31 and PE-22-28 target complementary aspects of brain health:

• SS-31 restores mitochondrial energy production, reduces neuroinflammation, and enhances plasticity.

• PE-22-28 increases serotonin, promotes neurogenesis, and strengthens memory circuits.

This combination suggests synergistic potential for improving mood, memory, and overall cognitive resilience.

PE-22-28 Safety in the Heart

Although TREK1 inhibition is often associated with dangerous QT prolongation in the heart, studies show that PE-22-28 avoids this side effect in animal models, supporting its safety profile for therapeutic use.

Conclusion

SS-31 and PE-22-28 both demonstrate powerful effects on mitochondrial function, neuroplasticity, and cardiovascular health. SS-31 counters oxidative stress, inflammation, and maladaptive calcineurin/NFAT signaling, while PE-22-28 boosts serotonin and hippocampal neurogenesis. Together, these peptides may offer a complementary therapeutic strategy for enhancing mood, protecting memory, and supporting heart function without significant safety concerns.